Atalanta Therapeutics raised $97 million in a Series B financing led by EQT Life Sciences and Sanofi Ventures to advance two RNAi therapies for KCNT1-related epilepsy and Huntington’s disease to clinical trials.
Amount Raised
$97 Million
Round Type
Series B
BostonBiotechnologyHealth CareTherapeuticsInvestors
Description
Atalanta Therapeutics has completed a $97 million Series B financing to support Phase 1 clinical trials of its RNAi therapies for neurological diseases. The funding will enable the company to progress its investigational therapies for KCNT1-related epilepsy and Huntington’s disease, aimed at addressing serious conditions lacking disease-modifying treatments.
Quick answer
Atalanta Therapeutics raised $97 Million in a Series B round, dated January 28, 2025. Investors: F Prime Capital, Ghr Foundation, Rivervest Venture Partners, Abrdn Inc., Novartis Venture Fund, Pictet Alternative Advisors, Mirae Asset Financial Group and EQT Life Sciences. Atalanta Therapeutics is based in Boston, Massachusetts, United States.
- How much did Atalanta Therapeutics raise?
- Atalanta Therapeutics raised $97 Million in a Series B round on January 28, 2025.
- Who invested in Atalanta Therapeutics?
- F Prime Capital, Ghr Foundation, Rivervest Venture Partners, Abrdn Inc., Novartis Venture Fund, Pictet Alternative Advisors, Mirae Asset Financial Group and EQT Life Sciences are named as investors in this round.
- What does Atalanta Therapeutics do?
- Atalanta Therapeutics is a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases.
- Where is Atalanta Therapeutics based and how big is it?
- Atalanta Therapeutics is based in Boston, Massachusetts, United States. Fundz records about 58 employees.
- Who are the decision-makers at Atalanta Therapeutics?
- Fundz holds 1 contact at Atalanta Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Atalanta Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- StimOxyGen raised $2M on March 11, 2025.
- HelloBetter raised $6.4M (Funding Round) on March 5, 2025.
- TRIMTECH Therapeutics raised $31M (Seed) on March 5, 2025.
- Whitehawk Therapeutics, Inc. raised $100M on March 4, 2025.
- Callio Therapeutics raised $187M (Series A) on March 3, 2025.
- Eikon Therapeutics raised $351M (Series D) on February 26, 2025.
Who to call at Atalanta Therapeutics, and when
A new round usually means Atalanta Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Atalanta Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Atalanta Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Atalanta Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Atalanta Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAtalanta Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.